JP2021511310A - 潰瘍性大腸炎を患っている患者を治療するための組成物、および薬物としての組成物の使用 - Google Patents
潰瘍性大腸炎を患っている患者を治療するための組成物、および薬物としての組成物の使用 Download PDFInfo
- Publication number
- JP2021511310A JP2021511310A JP2020539047A JP2020539047A JP2021511310A JP 2021511310 A JP2021511310 A JP 2021511310A JP 2020539047 A JP2020539047 A JP 2020539047A JP 2020539047 A JP2020539047 A JP 2020539047A JP 2021511310 A JP2021511310 A JP 2021511310A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dnazyme
- days
- administered
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 206010009900 Colitis ulcerative Diseases 0.000 title description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 title description 9
- 108091027757 Deoxyribozyme Proteins 0.000 claims abstract description 51
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 claims abstract description 21
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 18
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims description 26
- 208000028774 intestinal disease Diseases 0.000 claims description 18
- 208000037902 enteropathy Diseases 0.000 claims description 15
- 235000002639 sodium chloride Nutrition 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000000829 suppository Substances 0.000 claims description 6
- 241000792859 Enema Species 0.000 claims description 5
- 239000007920 enema Substances 0.000 claims description 5
- 229940095399 enema Drugs 0.000 claims description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 238000010586 diagram Methods 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 9
- 101100260032 Mus musculus Tbx21 gene Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 210000000447 Th1 cell Anatomy 0.000 description 5
- 210000004241 Th2 cell Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004610 GATA3 Transcription Factor Human genes 0.000 description 2
- 108010003338 GATA3 Transcription Factor Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007942 layered tablet Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 229960004995 magnesium peroxide Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940096976 rectal foam Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
当業者であれば、発現の下方制御が、発現の部分的な阻害または完全な阻害のいずれかを意味すると理解され得ることを認識している。いずれにせよ、自然な発現レベルと比較して、発現が有意に減少する。
組成物が水溶液の形態である場合も有利である。このような溶液の製造は、経済的かつ単純である。さらに、水溶液は増加した毒性を有さず、このことはこれが療法に使用するのに適していることを意味する。
本発明のさらなる特徴、詳細および利点は、特許請求の範囲の文言から、ならびに例示的な実施形態および図面の以下の説明から明らかになる。
(図2)図1の一連の実験の合計MAYOスコアの平均値を表で示す図である。
(図3)本発明による組成物を試験するための一連の実験からのシグモイド内視鏡MAYOスコアの平均値を棒グラフとして示す図である。
(図4)図3の一連の実験からの内視鏡MAYOスコアの平均値を表で示す図である。
そのため、組成物は、例えば、坐剤、滴剤、マウススプレー、鼻腔スプレー、丸剤、錠剤、フィルムコーティング錠、層状錠剤、坐剤、ゲル、軟膏、シロップ、吸入用粉末、顆粒剤、乳剤、分散剤、マイクロカプセル、カプセル剤、散剤、または注射用溶液の形態で製造および投与することができる。さらに、薬理学的に適合性の担体の群は、有効成分の制御放出および/または連続放出、ならびに特定の剤形としてのマイクロカプセル化のための層状錠剤などの製剤も包含する。
さらに、崩壊剤、着色剤、香味剤および/または結合剤を組成物にさらに添加することができる。使用される崩壊剤は、デンプン(トウモロコシ、ジャガイモおよびコムギデンプン、デンプングリコール酸ナトリウム)、例えばローカストビーンガム、カラヤ、グアー、トラガカントなどの天然および合成ガム、寒天、メチルセルロース、カルボキシメチルセルロースナトリウム、微結晶性セルロースなどのセルロース誘導体、アルギン酸塩、アルミナ、ベントナイト、PVP(ポリビニルピロリドン)、Carbopolおよび過酸化マグネシウムを含む群の物質である。これらの構成成分は、最大30%(w/w)の量で使用することができる。崩壊剤は、粒子付着を改善することによって、組成物の優れた圧縮性を保証する。崩壊剤はまた、例えば胃腸管における後の崩壊を促進する。崩壊剤は、水分を吸収し、毛管現象および膨潤を増加させる、またはガスの発生および水分の影響下での泡立ち、または親水化剤として錠剤の水和性を増加させることによって機能する。結合剤は、顆粒の凝集、および印加された圧力と共に錠剤強度を保証する。
使用される潤滑剤は、ホウ酸、ステアリン酸塩(例えば、ステアリン酸マグネシウム、ステアリン酸カルシウム、ステアリン酸カリウム)、ステアリン酸、高融点ワックス、および塩化ナトリウム、安息香酸ナトリウム、酢酸ナトリウム、オレイン酸ナトリウムを含む群の水溶性物質、ポリエチレングリコールおよびアミノ酸(例えば、ロイシン)を含む群の物質であり得る。潤滑剤は、最大15%(w/w)の量で使用することができる。
図1および図2に示される結果は、本発明による組成物が慢性炎症に関連する腸疾患を患っている患者を治療するのに適していることを印象的に実証している。
図3および図4は、図1および図2と同じ一連の実験に基づく。しかしながら、図3および図4に対応する結果は、別の観点から得られたものである。図3では、シグモイド内視鏡MAYOスコアの平均値が棒グラフで示されている。関連する測定データは図4に見られ得る。当業者であれば、「シグモイド」という用語が、ヒトの大腸の最後の部分であるS状結腸を意味すると理解する。内視鏡MAYOスコアの場合、内視鏡所見は疾患の典型的な特徴に関して評価される。
Claims (14)
- 慢性炎症に関連する腸疾患を患っている患者を治療するための組成物であって、GATA−3の発現を特異的に阻害する少なくとも1つのDNAザイムを含む組成物。
- 前記DNAザイムが配列hgd40(GTGGATGGAggctagctacaacgaGTCTTGGAG)を有することを特徴とする、請求項1に記載の組成物。
- 前記組成物中の前記DNAザイムの濃度が0.75mg/ml〜75mg/mlであることを特徴とする、請求項1または2に記載の組成物。
- 水溶液の形態であることを特徴とする、請求項1から3のいずれか一項に記載の組成物。
- 少なくとも1つの塩を含むことを特徴とする、請求項1から4のいずれか一項に記載の組成物。
- 前記塩が塩化ナトリウムおよび/または塩化カリウムおよび/またはリン酸塩であることを特徴とする、請求項5に記載の組成物。
- 直腸投与に適していることを特徴とする、請求項1から6のいずれか一項に記載の組成物。
- n日の所望の治療期間の場合、n日以下の投与期間、特にn/2日以下の投与期間にわたって投与されることを特徴とする、請求項1から7のいずれか一項に記載の組成物。
- 慢性炎症に関連する腸疾患を患っている患者を治療するための薬物としての、請求項1から9のいずれか一項に記載の組成物の使用。
- 前記組成物が坐剤の形態で投与されることを特徴とする、請求項9に記載の使用。
- 前記組成物が浣腸および/または注腸フォームの形態で投与されることを特徴とする、請求項10に記載の使用。
- 前記組成物が、前記DNAザイムの投与用量が1日当たり1患者当たり10mg〜500mgとなるように投与されることを特徴とする、請求項9から11のいずれか一項に記載の使用。
- 前記組成物が、n日の所望の治療期間の場合、n日以下の投与期間、特にn/2日以下の投与期間にわたって投与されることを特徴とする、請求項9から12のいずれか一項に記載の使用。
- 慢性炎症に関連する腸疾患を患っている患者の治療に使用するための、請求項1から8のいずれか一項に記載の組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023133181A JP2023156463A (ja) | 2018-01-18 | 2023-08-17 | 潰瘍性大腸炎を患っている患者を治療するための組成物、および薬物としての組成物の使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18152422.4 | 2018-01-18 | ||
EP18152422.4A EP3514235B8 (de) | 2018-01-18 | 2018-01-18 | Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel |
PCT/EP2019/050923 WO2019141674A1 (de) | 2018-01-18 | 2019-01-15 | Zusammensetzung zur behandlung eines an colitis ulcerosa leidenden patienten sowie verwendung der zusammensetzung als arzneimittel |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023133181A Division JP2023156463A (ja) | 2018-01-18 | 2023-08-17 | 潰瘍性大腸炎を患っている患者を治療するための組成物、および薬物としての組成物の使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021511310A true JP2021511310A (ja) | 2021-05-06 |
Family
ID=61054138
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020539047A Pending JP2021511310A (ja) | 2018-01-18 | 2019-01-15 | 潰瘍性大腸炎を患っている患者を治療するための組成物、および薬物としての組成物の使用 |
JP2023133181A Pending JP2023156463A (ja) | 2018-01-18 | 2023-08-17 | 潰瘍性大腸炎を患っている患者を治療するための組成物、および薬物としての組成物の使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023133181A Pending JP2023156463A (ja) | 2018-01-18 | 2023-08-17 | 潰瘍性大腸炎を患っている患者を治療するための組成物、および薬物としての組成物の使用 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20210177883A1 (ja) |
EP (1) | EP3514235B8 (ja) |
JP (2) | JP2021511310A (ja) |
KR (1) | KR20200110684A (ja) |
CN (1) | CN111630169A (ja) |
BR (1) | BR112020014583A8 (ja) |
CA (1) | CA3088576A1 (ja) |
PT (1) | PT3514235T (ja) |
RU (1) | RU2020127436A (ja) |
WO (1) | WO2019141674A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023052422A1 (en) | 2021-09-30 | 2023-04-06 | Sterna Biologicals Gmbh | Dnazyme hydrogel formulations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007507438A (ja) * | 2003-10-02 | 2007-03-29 | フィリップス−ウニベルジテート・マールブルク | 細胞および/または組織および/または疾患フェーズ特異的な薬剤の製造方法 |
JP2015531482A (ja) * | 2012-09-14 | 2015-11-02 | ステルナ ビオロジカルス ゲーエムベーハー ウント コー. カーゲー | 慢性炎症に伴う疾病の患者の分子表現型を診断する方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887906B1 (en) * | 1997-07-01 | 2005-05-03 | Isispharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
BR112017006272A2 (ja) * | 2014-09-29 | 2018-03-13 | Ea Pharma Co., Ltd. | The medicine constituent for medical treatment of chronic ulcerative colitis |
EP3463388A4 (en) * | 2016-05-24 | 2020-01-01 | Emory University | PARTICLES CONJUGATED TO RNA-DIVIDING NUCLEOBASE POLYMERS AND USES THEREOF IN THE MANAGEMENT OF INFLAMMATORY DISORDERS |
-
2018
- 2018-01-18 PT PT181524224T patent/PT3514235T/pt unknown
- 2018-01-18 EP EP18152422.4A patent/EP3514235B8/de active Active
-
2019
- 2019-01-15 CA CA3088576A patent/CA3088576A1/en active Pending
- 2019-01-15 JP JP2020539047A patent/JP2021511310A/ja active Pending
- 2019-01-15 RU RU2020127436A patent/RU2020127436A/ru unknown
- 2019-01-15 KR KR1020207023637A patent/KR20200110684A/ko not_active Application Discontinuation
- 2019-01-15 BR BR112020014583A patent/BR112020014583A8/pt not_active Application Discontinuation
- 2019-01-15 WO PCT/EP2019/050923 patent/WO2019141674A1/de active Application Filing
- 2019-01-15 US US16/962,849 patent/US20210177883A1/en not_active Abandoned
- 2019-01-15 CN CN201980009283.7A patent/CN111630169A/zh active Pending
-
2023
- 2023-08-17 JP JP2023133181A patent/JP2023156463A/ja active Pending
- 2023-10-17 US US18/488,067 patent/US20240041912A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007507438A (ja) * | 2003-10-02 | 2007-03-29 | フィリップス−ウニベルジテート・マールブルク | 細胞および/または組織および/または疾患フェーズ特異的な薬剤の製造方法 |
JP2015531482A (ja) * | 2012-09-14 | 2015-11-02 | ステルナ ビオロジカルス ゲーエムベーハー ウント コー. カーゲー | 慢性炎症に伴う疾病の患者の分子表現型を診断する方法 |
Non-Patent Citations (8)
Title |
---|
"History of Changes for Study: NCT02129439", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6022044229, 12 January 2017 (2017-01-12), ISSN: 0005038848 * |
"Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised tri", JOURNAL OF CROHN'S AND COLITIS, vol. Vol. 12, Issue supplement_1, JPN6022044228, 16 January 2018 (2018-01-16), pages 069 - 070, ISSN: 0005038847 * |
"Suppression of Experimental Ulcerative Colitis by Topical Delivery of Specific Dnazyme Blocking Thet", AGA ABSTRACTS, vol. Vol. 152, ISSUE 5, SUPPLEMENT 1, JPN6022044225, 2017, pages 758, ISSN: 0005038850 * |
「新医薬品の臨床評価に関する一般指針について」(薬新薬第四三号)各都道府県衛生主管部局長あて厚生省薬, JPN6021034322, 1992, pages 1 - 12, ISSN: 0005038852 * |
EXPERT OPINION ON DRUG DELIVERY, vol. 14, no. 9, JPN6022044230, 2017, pages 1077 - 1089, ISSN: 0005038849 * |
GASTROENTEROLOGY, vol. 152, JPN6022044226, 2017, pages 176 - 192, ISSN: 0005038845 * |
GUIDANCE FOR INDUSTRY, ESTIMATING THE MAXIMUM SAFE STARTING DOSE IN INITIAL CLINICAL TRIALS FOR THER, JPN6021034319, 2005, pages 1 - 27, ISSN: 0005038851 * |
NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY, JPN6022044227, 2016, ISSN: 0005038846 * |
Also Published As
Publication number | Publication date |
---|---|
US20240041912A1 (en) | 2024-02-08 |
PT3514235T (pt) | 2024-02-12 |
EP3514235A1 (de) | 2019-07-24 |
KR20200110684A (ko) | 2020-09-24 |
JP2023156463A (ja) | 2023-10-24 |
EP3514235B1 (de) | 2024-01-03 |
BR112020014583A2 (pt) | 2020-12-01 |
EP3514235B8 (de) | 2024-02-14 |
BR112020014583A8 (pt) | 2022-08-30 |
RU2020127436A (ru) | 2022-02-21 |
CA3088576A1 (en) | 2019-07-25 |
WO2019141674A1 (de) | 2019-07-25 |
CN111630169A (zh) | 2020-09-04 |
US20210177883A1 (en) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021513861A (ja) | Camk2dアンチセンスオリゴヌクレオチドおよびその使用 | |
EP2155225B1 (en) | Methods of treatment of skin ulcers | |
US20240041912A1 (en) | Composition for treating a patient suffering from ulcerative colitis, and use of the composition as a drug | |
EP3372234B1 (en) | Complex comprising rnai molecule and n-acetylated chitosan | |
JP6106671B2 (ja) | 粘膜治癒促進剤 | |
JP2020519619A (ja) | 炎症性腸疾患の治療における使用のためのコビトリモド | |
JP2008521927A (ja) | 炎症性腸疾患の治療のための治療用アンチセンスオリゴヌクレオチド組成物 | |
CN112203675A (zh) | 用于改善虚弱和衰老的方法 | |
JP2023503804A (ja) | Il-34アンチセンス薬剤、およびこれを使用する方法 | |
WO2007096596A2 (en) | Use of il-8 for the treatment of crohn' s disease | |
CN113226461A (zh) | 新疗法 | |
TW201032813A (en) | Treating picornavirus infection by targeting microrna miR-141 | |
KR102428121B1 (ko) | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료를 위한 딜리버리 시스템 | |
WO2018105708A1 (ja) | 慢性疾患の治療及び予防用医薬組成物 | |
US20120122787A1 (en) | Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases | |
KR102329524B1 (ko) | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 | |
CN117795077A (zh) | 包含修饰的rt-let7作为有效成分的用于预防或治疗肝癌的组合物 | |
WO2023046147A1 (zh) | 针对dkk1的适体及其用途 | |
IL292957A (en) | Treatment of heart disease | |
KR20230088810A (ko) | 마이크로rna-29 화합물, 조성물 및 요법에서의 용도 | |
JP5744560B2 (ja) | ファスシン(Fascin)遺伝子の働きを抑える短鎖RNAを含有する癌の予防、治療剤 | |
WO2023247736A1 (en) | Alpha1-antitrypsin for use in the treatment of diseases or disorders of the nervous system such as chronic inflammatory demyelinating polyneuropathy | |
KR20230049663A (ko) | saRNA 및 mRNA 조절제들에 의한 SMA의 조합 치료 | |
WO2023278802A1 (en) | Formulations for oral delivery of nucleic acids | |
US20160298120A1 (en) | Interferon Regulatory Factor 1 (IRF1) Decoys and Methods of Use Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221018 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230123 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230418 |